Department of Chemistry, GLA University, Mathura, Uttar Pradesh 281406, India.
Departments of Medical Oncology & Therapeutics Research and Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA.
Biochim Biophys Acta Rev Cancer. 2024 May;1879(3):189106. doi: 10.1016/j.bbcan.2024.189106. Epub 2024 May 1.
Cervical cancer remains a significant global health burden, necessitating innovative approaches for improved diagnostics and personalized treatment strategies. Precision medicine has emerged as a promising paradigm, leveraging biomarkers and molecular targets to tailor therapy to individual patients. This review explores the landscape of emerging biomarkers and molecular targets in cervical cancer, highlighting their potential implications for precision medicine. By integrating these biomarkers into comprehensive diagnostic algorithms, clinicians can identify high-risk patients at an earlier stage, enabling timely intervention and improved patient outcomes. Furthermore, the identification of specific molecular targets has paved the way for the development of targeted therapies aimed at disrupting key pathways implicated in cervical carcinogenesis. In conclusion, the evolving landscape of biomarkers and molecular targets presents exciting opportunities for advancing precision medicine in cervical cancer. By harnessing these insights, clinicians can optimize treatment selection, enhance patient outcomes, and ultimately transform the management of this devastating disease.
宫颈癌仍然是一个重大的全球健康负担，需要创新的方法来改善诊断和制定个性化的治疗策略。精准医学已经成为一种有前途的模式，利用生物标志物和分子靶标来针对个体患者进行治疗。本综述探讨了宫颈癌中新兴生物标志物和分子靶标的研究现状，强调了它们对精准医学的潜在影响。通过将这些生物标志物整合到综合诊断算法中，临床医生可以更早地识别高危患者，从而实现及时干预和改善患者预后。此外，特定分子靶标的鉴定为开发旨在阻断宫颈癌发生中关键途径的靶向治疗铺平了道路。总之，生物标志物和分子靶标的不断发展为宫颈癌精准医学的发展带来了令人兴奋的机遇。通过利用这些见解，临床医生可以优化治疗选择，提高患者的治疗效果，最终改变这种毁灭性疾病的管理方式。
